Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06642480
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
Distribution of CYP2D6 Multiplication CYP2D65 and Clinical Implications in Postoperative Patients Receiving Tramadol Analgesia in the Minangkabau Ethnic Group Indonesia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Determination of Patients39 Visual Analogue Scale VAS in Postoperative Patients Receiving Tramadol Analgesia in the Minangkabau Ethnic Group Indonesia
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Tramadol
Brief Summary:
Cytochrome P450 2D6 CYP2D6 is an important enzyme in metabolizing commonly used drugs such as Tramadol hydrochloride widely used opioid analgesic Genetic polymorphisms of the CYP2D6 gene have been shown to influence the pharmacodynamic properties of the administered drug This study aimed to screen 63 postoperative patients wild-type CYP2D65 and CYP2D6 multiplication of Minangkabau ethnicity in West Sumatera Indonesia who received tramadol using a modified long PCR method and to investigate the clinical impact of tramadol on the patients
Detailed Description:
VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed It was observed in the recovery room at 30 60 and 120 minutes Tramadol had an onset time of 15-60 minutes with peak effectiveness at 2-6 hours postoperatively Pain level was categorized into 0 no pain 1-3 signifying mild 4-6 middle and 7-10 heavy pain
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None